Les médicaments radiopharmaceutiques ciblant les récepteurs peptidiques tels que les analogues de la somatostatine ont un réel potentiel et un fort intérêt pour à la fois le diagnostic et le traitement des tumeurs neuroendocrines (TNE) non-opérables, par radiothérapie interne vectorisée (RIV). La toxicité des traitements par radiopeptides analogues de la somatostatine limite leur développement clinique. Le développement de nouveaux peptides ciblant d'autres types de récepteurs tels que le ceux de la cholécystokinine (CCK) est une solution dont l'intérêt a été montré par les travaux de notre équipe, basés sur un analogue CCK novateur. Ce travail en trois volets décrit dans un premier temps le radiomarquage de l'analogue CCK, par des radionucléides émetteurs - tels que l'yttrium 90 et le lutétium 177 adaptés à la thérapie, en plus de l'indium 111 pour le diagnostic, les capacités de complexation et la stabilité de ce nouvel analogue peptidique CCK. Une étude in vivo préliminaire sur modèle murin a permis d'étudier la faisabilité d'un traitement de RIV. Une troisième étude a été réalisée in vitro sur deux lignées cellulaires tumorales par le traitement à l'aide d'une molécule antitumorale caractérisée dans notre équipe, à travers la réexpression d'une voie de signalisation cellulaire. Ce travail a permis de montrer l'intérêt potentiel de l'utilisation des analogues CCK en RIV en association thérapeutique pour la prise en charge de certaines TNE. / Les médicaments radiopharmaceutiques ciblant les récepteurs peptidiques tels que les analogues de la somatostatine ont un réel potentiel et un fort intérêt pour à la fois le diagnostic et le traitement des tumeurs neuroendocrines (TNE) non-opérables, par radiothérapie interne vectorisée (RIV). La toxicité des traitements par radiopeptides analogues de la somatostatine limite leur développement clinique. Le développement de nouveaux peptides ciblant d'autres types de récepteurs tels que le ceux de la cholécystokinine (CCK) est une solution dont l'intérêt a été montré par les travaux de notre équipe, basés sur un analogue CCK novateur. Ce travail en trois volets décrit dans un premier temps le radiomarquage de l'analogue CCK, par des radionucléides émetteurs - tels que l'yttrium 90 et le lutétium 177 adaptés à la thérapie, en plus de l'indium 111 pour le diagnostic, les capacités de complexation et la stabilité de ce nouvel analogue peptidique CCK. Une étude in vivo préliminaire sur modèle murin a permis d'étudier la faisabilité d'un traitement de RIV. Une troisième étude a été réalisée in vitro sur deux lignées cellulaires tumorales par le traitement à l'aide d'une molécule antitumorale caractérisée dans notre équipe, à travers la réexpression d'une voie de signalisation cellulaire. Ce travail a permis de montrer l'intérêt potentiel de l'utilisation des analogues CCK en RIV en association thérapeutique pour la prise en charge de certaines TNE.

<p>Liquid chromatography – mass spectrometry (LC-MS) methods were developed for the analysis of positron emission tomography (PET) radiotracers in biological matrices. Additionally, radiotracer chemistry was explored as an analytical tool for supporting LC-MS method development and imaging molecular interactions in miniaturised chemical analysis systems.</p><p>Conventional radiodetection methods can offer high sensitivity in the analysis of radiotracers in biological matrices, although with the short half-life of PET tracers, this mass sensitivity decreases rapidly with time. This limits the time frame for analysis, and may compromise the precision and accuracy of the later measurements. Performing LC-MS analysis of the dominant stable isotope form of the tracer removes such time restrictions.</p><p>An LC-MS/MS method was developed for determination of the tracer flumazenil in human plasma, with high inter-assay precision (RSD < 7%) and accuracy (95 – 104%). The method was applied in a multiple scan PET study where the plasma concentration spanned from 0.07 to 0.21 nM. The method removed the time restrictions associated with radiodetection methods and thus provided the opportunity of analysing a greater number of samples than would have been possible with radioanalysis.</p><p>Furthermore, an LC-MS/MS method was developed that provided an efficient metabolic screening tool of potential PET tracers, whereby the substrates could be collected directly from 11C-labelling batches. This permitted repeated incubation experiments without the need of repeated labelling syntheses. A para-methoxy-benzamide analogue of the radiotracer WAY-100635 was thus identified as a potential tracer with improved metabolic stability. Additionally, a capillary LC-MS method was developed with rapid (0.75 min) and efficient (> 99%) on-line high flow-rate extraction for determination of metabolic stability of PET radiotracers.</p><p>Finally, the concept of radionuclide imaging of miniaturised chemical analysis systems was demonstrated with the direct study of interactions within capillary extraction columns and microchannels moulded in a plastic CD and poly(dimethylsiloxane).</p>

<p>The overall objective of the current study is to develop a quantitative understanding of the effects of spatial variability in physical and geochemical properties of crystalline rock on the migration of radionuclides along a single fracture in bedrock. A stochastic model was developed to describe the transport of solutes in fractured rock. The model describes the migration of radionuclides along a one-dimensional path and includes the transversal diffusion into the rock matrix and sorption kinetics. By using a Lagrangian method of description we can extend the model to the description of a two-dimensional transport problem in single fractures. </p><p>This study presents the first analysis of the impact of heterogeneous mass transfer on the transport of radionuclides in rock fractures, where most of the relevant rock properties such as aperture, porosity, effective diffusivity, sorption capacity and maximum diffusion depth are defined as being spatially random. The stochastic analysis performed here reflects the uncertainty in our knowledge of the properties associated with a discrete sampling technique in site investigations.</p><p>Geostatistics of the main parameters was determined experimentally on a large number of rock samples taken from the Swedish crystalline basement. The knowledge of the covariance functions of the main rock properties is then used as a basis for a stochastic analysis. By combining the small perturbation approach with the spectral method the problem could be solved in terms of closed form solutions for the central temporal moments of the residence time probability density function. </p><p>In order to be able to distinguish between the effects of various mechanisms from the effects of heterogeneity on the migration of radionuclides, it was necessary to perform independent studies of the effect of the variation of the dispersion coefficient on the aspect ratio of a rectangular flow section and the effect of adsorption kinetics on the migration. </p><p>Finally, the effect of the heterogeneous rock properties on the solute transport observed in a limited number of migration experiments corresponds fairly well to the theoretical effect expected on the basis of the experimentally determined auto-covariance functions. </p>

The overall objective of the current study is to develop a quantitative understanding of the effects of spatial variability in physical and geochemical properties of crystalline rock on the migration of radionuclides along a single fracture in bedrock. A stochastic model was developed to describe the transport of solutes in fractured rock. The model describes the migration of radionuclides along a one-dimensional path and includes the transversal diffusion into the rock matrix and sorption kinetics. By using a Lagrangian method of description we can extend the model to the description of a two-dimensional transport problem in single fractures. This study presents the first analysis of the impact of heterogeneous mass transfer on the transport of radionuclides in rock fractures, where most of the relevant rock properties such as aperture, porosity, effective diffusivity, sorption capacity and maximum diffusion depth are defined as being spatially random. The stochastic analysis performed here reflects the uncertainty in our knowledge of the properties associated with a discrete sampling technique in site investigations. Geostatistics of the main parameters was determined experimentally on a large number of rock samples taken from the Swedish crystalline basement. The knowledge of the covariance functions of the main rock properties is then used as a basis for a stochastic analysis. By combining the small perturbation approach with the spectral method the problem could be solved in terms of closed form solutions for the central temporal moments of the residence time probability density function. In order to be able to distinguish between the effects of various mechanisms from the effects of heterogeneity on the migration of radionuclides, it was necessary to perform independent studies of the effect of the variation of the dispersion coefficient on the aspect ratio of a rectangular flow section and the effect of adsorption kinetics on the migration. Finally, the effect of the heterogeneous rock properties on the solute transport observed in a limited number of migration experiments corresponds fairly well to the theoretical effect expected on the basis of the experimentally determined auto-covariance functions.

Liquid chromatography – mass spectrometry (LC-MS) methods were developed for the analysis of positron emission tomography (PET) radiotracers in biological matrices. Additionally, radiotracer chemistry was explored as an analytical tool for supporting LC-MS method development and imaging molecular interactions in miniaturised chemical analysis systems. Conventional radiodetection methods can offer high sensitivity in the analysis of radiotracers in biological matrices, although with the short half-life of PET tracers, this mass sensitivity decreases rapidly with time. This limits the time frame for analysis, and may compromise the precision and accuracy of the later measurements. Performing LC-MS analysis of the dominant stable isotope form of the tracer removes such time restrictions. An LC-MS/MS method was developed for determination of the tracer flumazenil in human plasma, with high inter-assay precision (RSD &lt; 7%) and accuracy (95 – 104%). The method was applied in a multiple scan PET study where the plasma concentration spanned from 0.07 to 0.21 nM. The method removed the time restrictions associated with radiodetection methods and thus provided the opportunity of analysing a greater number of samples than would have been possible with radioanalysis. Furthermore, an LC-MS/MS method was developed that provided an efficient metabolic screening tool of potential PET tracers, whereby the substrates could be collected directly from 11C-labelling batches. This permitted repeated incubation experiments without the need of repeated labelling syntheses. A para-methoxy-benzamide analogue of the radiotracer WAY-100635 was thus identified as a potential tracer with improved metabolic stability. Additionally, a capillary LC-MS method was developed with rapid (0.75 min) and efficient (&gt; 99%) on-line high flow-rate extraction for determination of metabolic stability of PET radiotracers. Finally, the concept of radionuclide imaging of miniaturised chemical analysis systems was demonstrated with the direct study of interactions within capillary extraction columns and microchannels moulded in a plastic CD and poly(dimethylsiloxane).

Developing radiation delivery systems for optimisation of absorbed dose to the target without normal tissue toxicity requires advanced calculations for transport of radiation. In this thesis absorbed dose and fluence in different radiotherapy applications were calculated by using Monte Carlo (MC) simulations. In paper I-III external neutron activation of gadolinium (Gd) for intravascular brachytherapy (GdNCB) and tumour therapy (GdNCT) was investigated. MC codes MCNP and GEANT4 were compared. MCNP was chosen for neutron capture reaction calculations. Gd neutron capture reaction includes both very short range (Auger electrons) and long range (IC electrons and gamma) products. In GdNCB the high-energetic gamma gives an almost flat absorbed dose delivery pattern, up to 4 mm around the stent. Dose distribution at the edges and inside the stent may prevent stent edge and in-stent restenosis. For GdNCT the absorbed dose from prompt gamma will dominate over the dose from IC and Auger electrons in an in vivo situation. The absorbed dose from IC electrons will enhance the total absorbed dose in the tumours and contribute to the cell killing. In paper IV a model for calculation of inter-cluster cross-fire radiation dose from β-emitting radionuclides in a breast cancer model was developed. GEANT4 was used for obtaining absorbed dose. The dose internally in cells binding the isotope (self-dose) increased with decreasing β-energy except for the radionuclides with substantial amounts of conversion electrons and Auger electrons. An effective therapy approach may be a combination of radionuclides where the high self-dose from nuclides with low β-energy should be combined with the inter-cell cluster cross-fire dose from high energy β-particles. In paper V MC simulations using correlated sampling together with importance sampling were used to calculate spectra perturbations in detector volumes caused by the detector silicon chip and its encapsulation. Penelope and EGSnrc were used and yielded similar results. The low energy part of the electron spectrum increased but to a less extent if the silicon detector was encapsulated in low z-materials.

Manmade radionuclides have been introduced to the environment for almost a century. The main source has been the nuclear weapons testing programmes, but accidental releases from the nuclear power production industries have also contributed. The risk to humans from potential releases from nuclear facilities is evaluated in safety assessments. Essential components of these assessments are exposure models, which estimate the transport of radionuclides in the environment, the uptake in biota, and transfer to humans. Recently, there has been a growing concern for radiological protection of the whole environment, not only humans, and a first attempt has been to employ model approaches based on stylised environments and transfer functions to biota based exclusively on bioconcentration factors. They are generally of a non-mechanistic nature and involve no knowledge of the actual processes involved, which is a severe limitation when assessing real ecosystems. The research presented in this thesis attempts to introduce a methodology for modelling exposure of biota that is based on systems ecological theories and concepts. All presented papers concern bioaccumulation and circulation of radionuclides in coastal areas of the Baltic Sea, which is a sea surrounded by several nuclear power plants, waste repositories and reprocessing facilities. Paper I illustrates how an ecosystem model can be used to predict the fate of C-14 in a bay, and to explore the influence of uptake route and water exchange on the concentrations in biota. Due to the longevity of many radionuclides, time spans of thousands of years need to be considered in assessments of nuclear waste facilities. In Paper II, the methodological problems associated with these long timescales are discussed and a new modelling approach is proposed. An extension and generalisation of the C-14 flow model into a generic model for other radionuclides is described and tested in Paper III. This paper also explores the importance of three radionuclide specific mechanisms (plant uptake, excretion and adsorption to organic surfaces) for the concentrations in biota. In Paper IV, the bioaccumulation kinetics of three radionuclides in three key benthic species of the Baltic Sea is studied experimentally. Paper V considers remobilisation and redistribution of sediment-associated radionuclides due to biological mixing, in a microcosm study. The findings in this thesis show both that it was possible to use an ecosystem approach to assess the exposure to biota, and that this approach can handle many of the problems identified in the use of traditional exposure models for radionuclides. To conclude, frameworks for the protection of the environment from ionising radiation would benefit from implementing methodologies based on ecologically sound principles and modelling techniques.

Radionuclide molecular imaging is an emerging multidisciplinary technique that is used in modern medicine to visualise diseases at cellular and molecular levels. This thesis is based on five papers (I-V) and focuses on the development of site-specific radiolabelled recombinant anti-HER2 Affibody molecules and preclinical evaluations in vitro and in vivo of the labelled conjugates. This work is part of a preclinical development of an Affibody molecule-based tracer for molecular imaging of HER2 expressing tumours. Papers I and II report the evaluation of the Affibody molecule ZHER2:2395-C, site-specifically labelled with the radiometals 111In (for SPECT) and 57Co (as a surrogate for 55Co, suitable for PET applications) using a thiol reactive DOTA derivative as a chelator. Both conjugates demonstrated very suitable biodistribution properties, enabling high contrast imaging just a few hours after injection. Papers III and IV report the development and optimization of a technique for site-specific labelling of ZHER2:2395-C with 99mTc using an N3S chelating peptide sequence. 99mTc-ZHER2:2395-C demonstrated high and specific tumour uptake and rapid clearance of non-bound tracer from the blood, resulting in high tumour-to-non-tumour ratios shortly after injection, enabling high contrast imaging. In addition, in the study described in paper IV, freeze-dried kits previously developed for 99mTc-labelling were optimised, resulting in the development of a kit in which all the reagents and protein needed for labelling of ZHER2:2395-C with 99mTc were contained in a single vial. Paper V reports the evaluation of an anti-HER2 Affibody molecule, ABY-025, with a fundamentally re-engineered scaffold. Despite the profound re-engineering, the biodistribution pattern of 111In-ABY-025 was very similar to that of two variants of the parental molecule. It seems reasonable to believe that these results will also be applicable to Affibody molecules towards other targets. Hopefully, this work will also be helpful in the development of other small proteinaceous tracers.

The overexpression of the human epidermal growth factor receptor-2 (HER-2) in 20-25% of human breast cancers was investigated as a target for development of a gold nanoparticle (AuNP) based radiosensitizer for improving the efficacy of neoadjuvant X-radiation therapy of the disease. HER-2 targeted AuNPs were developed by covalently conjugating trastuzumab, a Health Canada approved monoclonal antibody for the treatment of HER-2-overexpressing breast cancer, to 30 nm AuNPs. Trastuzumab conjugated AuNPs were efficiently internalized by HER-2-overexpressing breast cancer cells (as assessed by darkfield microscopy and transmission electron microscopy) and increased DNA damage from X-radiation in these cells by more than 5-fold. To optimize delivery of AuNPs to HER-2-overexpressing tumors, high resolution microSPECT/CT imaging was used to track the in vivo fate of 111In-labelled non-targeted and HER-2 targeted AuNPs following intravenous (i.v.) or intratumoral (i.t.) injection. For i.v. injection, the effects of GdCl3 (for deactivation of macrophages) and non-specific (anti-CD20) antibody rituximab (for blocking of Fc mediated liver and spleen uptake) were studied. It was found that HER-2 targeting via attachment of trastuzumab paradoxically decreased tumor uptake as a result of faster elimination of the targeted AuNPs from the blood while improving internalization in HER-2-positive tumor cells as compared to non-targeted AuNPs. This phenomenon could be attributed to Fc-mediated recognition and subsequent sequestration of trastuzumab conjugated AuNP by the reticuloendothelial system (RES). Blocking of the RES did not increase tumor uptake of either HER-2 targeted or non-targeted AuNPs. Following i.t. injection, our results suggest that Au-NTs redistribute over time and traffick to the liver via the ipsilateral axillary lymph node leading to comparable exposure as seen with i.v. administration. In contrast, targeted AuNPs are bound and internalized by HER-2-overexpressing tumor cells following i.t. injection, with a lower proportion of AuNPs redistributing to normal tissues. In vivo, the combination of HER-2 targeted AuNPs injected i.t. and X-radiation (11 Gy) yielded a 46% decrease in tumor size over a 4 month period in contrast to an 11.5% increase in tumor size for X-radiation treatment alone. Toxicology studies (evaluated through complete blood cell counts, by serum transaminase and creatinine measurements and by monitoring the body weight) demonstrated no apparent normal organ toxicity from the combination of HER-2 targeted AuNPs and X-radiation. These results are promising for the clinical translation of HER-2-targeted AuNPs for radiosensitization of tumors to X-radiation.

Thesis (D.Tech.: Radiography)-Dept. of Radiography, Durban Institute of Technology, 2006 xxiii, 166 leaves / The purpose of this study was to evaluate 99mTc- methoxyisobutylisonitrile (MIBI) imaging, in terms of sensitivity and specificity, for non invasively detecting extracutaneous involvement of Kaposi’s sarcoma (KS) and for differentiating pulmonary infection from malignancy in acquired immunodeficiency syndrome (AIDS) patients before and after treatment. Current investigations are invasive.